The Department of Justice, led by Attorney General Todd Blanche in the Trump administration, issued a final order on April 23, 2026, rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, following HHS's scientific and medical evaluation and over 43,000 public comments. This partial reform eases some research, banking, and Section 280E tax barriers but leaves broader rescheduling of marijuana from Schedule I unresolved. A pivotal DEA administrative hearing begins June 29, 2026, in Arlington, Virginia, to assess full reclassification, amid emerging legal challenges and state implementation efforts that could influence federal drug policy trajectory and market resolution.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$758,306 Wol.
Mar 31, 2026
June 30
2%
December 31
25%
$758,306 Wol.
June 30
$336,932 Wol.
2%
December 31
$156,491 Wol.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice, led by Attorney General Todd Blanche in the Trump administration, issued a final order on April 23, 2026, rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, following HHS's scientific and medical evaluation and over 43,000 public comments. This partial reform eases some research, banking, and Section 280E tax barriers but leaves broader rescheduling of marijuana from Schedule I unresolved. A pivotal DEA administrative hearing begins June 29, 2026, in Arlington, Virginia, to assess full reclassification, amid emerging legal challenges and state implementation efforts that could influence federal drug policy trajectory and market resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$758,306Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice, led by Attorney General Todd Blanche in the Trump administration, issued a final order on April 23, 2026, rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, following HHS's scientific and medical evaluation and over 43,000 public comments. This partial reform eases some research, banking, and Section 280E tax barriers but leaves broader rescheduling of marijuana from Schedule I unresolved. A pivotal DEA administrative hearing begins June 29, 2026, in Arlington, Virginia, to assess full reclassification, amid emerging legal challenges and state implementation efforts that could influence federal drug policy trajectory and market resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$758,306Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Department of Justice, led by Attorney General Todd Blanche in the Trump administration, issued a final order on April 23, 2026, rescheduling FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, following HHS's scientific and medical evaluation and over 43,000 public comments. This partial reform eases some research, banking, and Section 280E tax barriers but leaves broader rescheduling of marijuana from Schedule I unresolved. A pivotal DEA administrative hearing begins June 29, 2026, in Arlington, Virginia, to assess full reclassification, amid emerging legal challenges and state implementation efforts that could influence federal drug policy trajectory and market resolution.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania